
Diego R Falci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6550830/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. Lancet Microbe, The, 2022, 3, e464-e470.	3.4	35
2	OUP accepted manuscript. Medical Mycology, 2022, , .	0.3	2
3	High rate of Clostridioides difficile colonization in patients admitted to intensive care: A prospective cohort study. Anaerobe, 2022, , 102538.	1.0	1
4	The era of histoplasmosis in Brazilian endemic mycoses. The Lancet Regional Health Americas, 2021, 3, 100037.	1.5	2
5	Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. New England Journal of Medicine, 2021, 385, 1941-1950.	13.9	832
6	Cranial syphilitic gumma. International Journal of Infectious Diseases, 2020, 95, 160-161.	1.5	1
7	Clinical Characteristics of Covid-19 in China. New England Journal of Medicine, 2020, 382, 1859-1862.	13.9	275
8	Genetic relatedness, Virulence factors and Antimicrobial Resistance of C. difficile strains from hospitalized patients in a multicentric study in Brazil. Journal of Global Antimicrobial Resistance, 2020, 22, 117-121.	0.9	11
9	Candidaemia Mortality Has not Changed Over the Last 2ÂDecades in Brazil. Mycopathologia, 2020, 185, 685-690.	1.3	2
10	Early antiretroviral therapy for HIV-infected patients admitted to an intensive care unit (EARTH-ICU): A randomized clinical trial. PLoS ONE, 2020, 15, e0239452.	1.1	4
11	Title is missing!. , 2020, 15, e0239452.		0
12	Title is missing!. , 2020, 15, e0239452.		0
13	Title is missing!. , 2020, 15, e0239452.		0
14	Title is missing!. , 2020, 15, e0239452.		0
15	Impact of extended-spectrum β-lactamases and carbapenem-resistant Gram-negative infections on sepsis mortality at the emergency department: a cohort study. Journal of Hospital Infection, 2019, 101, 190-191.	1.4	3
16	Clinical Use of Polymyxin B. Advances in Experimental Medicine and Biology, 2019, 1145, 197-218.	0.8	25
17	High frequency of Clostridium difficile infections in Brazil: Results from a multicenter point-prevalence study. Infection Control and Hospital Epidemiology, 2019, 40, 484-485.	1.0	7
18	Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity. Antibiotics, 2019, 8, 24.	1.5	76

DIEGO R FALCI

#	Article	IF	CITATIONS
19	Histoplasmosis, An Underdiagnosed Disease Affecting People Living With HIV/AIDS in Brazil: Results of a Multicenter Prospective Cohort Study Using Both Classical Mycology Tests and Histoplasma Urine Antigen Detection. Open Forum Infectious Diseases, 2019, 6, ofz073.	0.4	55
20	Clinical mycology in Latin America and the Caribbean: AÂsnapshot of diagnostic and therapeutic capabilities. Mycoses, 2019, 62, 368-373.	1.8	34
21	Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents, 2019, 53, 152-157.	1.1	35
22	Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery. International Journal of Antimicrobial Agents, 2018, 52, 86-89.	1.1	8
23	Hypervirulent Clostridium difficile Strain Has Arrived in Brazil. Infection Control and Hospital Epidemiology, 2018, 39, 371-373.	1.0	14
24	Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	36
25	417. Clinical Mycology in Latin America and the Caribbean: Diagnostic Capabilities and Antifungal Therapy. Open Forum Infectious Diseases, 2018, 5, S159-S159.	0.4	1
26	A Review of Diagnostic Methods for Invasive Fungal Diseases: Challenges and Perspectives. Infectious Diseases and Therapy, 2017, 6, 213-223.	1.8	11
27	Absence of Correlation Between Vancomycin Consumption and Minimum Inhibitory Concentration of Methicillin-Resistant Staphylococcus aureus Isolates. Infection Control and Hospital Epidemiology, 2017, 38, 751-753.	1.0	1
28	Malaria in Southern Brazil: a potential threat for a non-endemic region. Brazilian Journal of Infectious Diseases, 2017, 21, 678-679.	0.3	1
29	Neglected endemic mycoses. Lancet Infectious Diseases, The, 2017, 17, e367-e377.	4.6	199
30	Disseminated histoplasmosis and <scp>AIDS</scp> : a prospective and multicentre study to evaluate the performance of different diagnostic tests. Mycoses, 2017, 60, 20-24.	1.8	17
31	Progressive disseminated histoplasmosis: a systematic review on the performance of non-culture-based diagnostic tests. Brazilian Journal of Infectious Diseases, 2017, 21, 7-11.	0.3	27
32	Characteristics of serogroup 20 S.pneumoniae isolates from Brazil. BMC Infectious Diseases, 2016, 16, 418.	1.3	4
33	Has Aspergillus PCR Come to the Age of Maturity?. Mycopathologia, 2016, 181, 623-624.	1.3	5
34	Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B. International Journal of Antimicrobial Agents, 2016, 47, 146-150.	1.1	18
35	Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. Antimicrobial Agents and Chemotherapy, 2016, 60, 2443-2449.	1.4	104
36	<i>Lactobacillus rhamnosus</i> bacteremia in a kidney transplant recipient. Transplant Infectious Disease, 2015, 17, 610-612.	0.7	11

DIEGO R FALCI

#	Article	IF	CITATIONS
37	The Evolving Genotypic Profile of HIV-1 Mutations Related to Antiretroviral Treatment in the North Region of Brazil. BioMed Research International, 2015, 2015, 1-6.	0.9	13
38	Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. Journal of Antimicrobial Chemotherapy, 2015, 70, 1552-1557.	1.3	98
39	Hematological toxicities associated with amphotericin B formulations. Leukemia and Lymphoma, 2015, 56, 2889-2894.	0.6	22
40	Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a realâ€life study. Mycoses, 2015, 58, 104-112.	1.8	47
41	Head and Neck Hyperpigmentation Probably Associated With Polymyxin B Therapy. Annals of Pharmacotherapy, 2015, 49, 1171-1172.	0.9	20
42	Burden of isolation for multidrug-resistant organisms in a tertiary public hospital in Southern Brazil. American Journal of Infection Control, 2015, 43, 188-190.	1.1	4
43	Detection of <i>bla</i> _{GES-5} in Carbapenem-Resistant Kluyvera intermedia Isolates Recovered from the Hospital Environment. Antimicrobial Agents and Chemotherapy, 2014, 58, 622-623.	1.4	21
44	Heteroresistance to Carbapenems in New Delhi Metallo-β-Lactamase-1–Producing Isolates: A Challenge for Detection?. Infection Control and Hospital Epidemiology, 2014, 35, 751-752.	1.0	7
45	Detection of OXA-370, an OXA-48-Related Class D β-Lactamase, in Enterobacter hormaechei from Brazil. Antimicrobial Agents and Chemotherapy, 2014, 58, 3566-3567.	1.4	33
46	Detection of NDM-1-, CTX-M-15-, and <i>qnrB4</i> -Producing Enterobacter hormaechei Isolates in Brazil. Antimicrobial Agents and Chemotherapy, 2014, 58, 2475-2476.	1.4	38
47	Carbapenem-resistant GES-5-producing Klebsiella pneumoniae in Southern Brazil. Brazilian Journal of Infectious Diseases, 2014, 18, 231-232.	0.3	12
48	Emergence of NDM-1-producing Enterobacteriaceae in Porto Alegre, Brazil. International Journal of Infectious Diseases, 2014, 25, 79-81.	1.5	44
49	Isolation of NDM-producing Providencia rettgeri in Brazil. Journal of Antimicrobial Chemotherapy, 2013, 68, 2956-2957.	1.3	83
50	Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens. Clinical Infectious Diseases, 2013, 57, 524-531.	2.9	351
51	Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. Journal of Antimicrobial Chemotherapy, 2013, 68, 674-677.	1.3	63
52	Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infection and Drug Resistance, 2013, 6, 163.	1.1	91
53	Polymyxin B Consumption and Incidence of Gram-Negative Bacteria Intrinsically Resistant to Polymyxins. Infection Control and Hospital Epidemiology, 2012, 33, 536-537.	1.0	1
54	Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment. Mycoses, 2011, 54, 91-98.	1.8	12

DIEGO R FALCI

#	Article	IF	CITATIONS
55	Continuous Infusion of Amphotericin B Deoxycholate in the Treatment of Cryptococcal Meningoencephalitis: Analysis of Safety and Fungicidal Activity. Clinical Infectious Diseases, 2010, 50, e26-e29.	2.9	14
56	Chronic slowly progressive monoarthritis tuberculosis of the hip without systemic symptoms mimicking osteoarthritis: a case report. Cases Journal, 2009, 2, 6457.	0.4	2
57	Continuous Infusion of Amphotericin B deoxycholate in the Treatment of Cryptococcal Meningoencephalitis: Analysis of Safety and Fungicidal Activity. International Journal of Infectious Diseases, 2008, 12, e282-e283.	1.5	2